Relapsing hematologic malignancies after haploidentical hematopoietic stem cell transplantation.

Haploidentical hematopoietic stem cell transplantation (HSCT) is a potentially curative therapeutic regimen that could increase donor availability to nearly 100%. Rapid advances in medical technology and the application of novel drugs mean that most haploidentical HSCT-associated complications can now be prevented or remarkably well controlled, even cured. However, relapsing hematologic malignancy remains a major cause of death in haploidentical HSCT recipients. Haploidentical HSCT should theoretically trigger a more potent graft-versus-tumor effect compared with human leukocyte antigen-identical transplantation, due mainly to the major histocompatibility complex and minor histocompatibility anitigen disparities on donors' immune cells and recipients' tumor cells. The underlying mechanisms of such relapsing hematologic malignancies remain elusive. In this review, we suggest correlating factors and potential mechanisms and examine feasible therapeutic and preventive strategies for relapsing hematologic malignancies after haploidentical HSCT.

• Publication year

  2011

• Venue

  Biology of Blood and Marrow Transplantation

• Publication date

  2011-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.bbmt.2011.02.013PMID 21440653
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immune reconstitution after haploidentical hematopoietic cell transplantation: impact of reduced intensity conditioning and CD3/CD19 depleted grafts

  2011cited by this paper
• On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies.

  2011cited by this paper
• High-dose chemotherapy with autologous stem cell rescue for relapse after allo-SCT in multiple myeloma

  2011cited by this paper
• Long-term follow-up of a pilot study using a chemotherapy-alone protocol for killer Ig-like receptor-ligand-mismatched haploidentical haematopoietic SCT

  2011cited by this paper
• Graft-Versus-Leukemia Effect on Infant Lymphoblastic Leukemia Relapsed After Sibling Hematopoietic Stem Cell Transplantation

  2010cited by this paper
• In vivo manipulation of Vγ9Vδ2 T cells with zoledronate and low‐dose interleukin‐2 for immunotherapy of advanced breast cancer patients

  2010cited by this paper
• Haploidentical Transplantation for Leukemia

  2010cited by this paper
• Diverging effects of HLA–DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles

  2010cited by this paper
• NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus

  2010cited by this paper
• Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation.

  2010cited by this paper
• FLT3 as a therapeutic target in AML: still challenging after all these years.

  2010cited by this paper
• Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation.

  2010cited by this paper
• Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT

  2010cited by this paper
• Haploidentical hematopoietic stem cell transplantation to adults with hematologic malignancies: analysis of 66 cases at a single Japanese center

  2010cited by this paper
• Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantation.

  2010cited by this paper
• Vg9Vd2 T Lymphocytes Efficiently Recognize and Kill Zoledronate-Sensitized, Imatinib-Sensitive, and Imatinib-Resistant Chronic Myelogenous Leukemia Cells

  2010cited by this paper
• HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome

  2010cited by this paper
• Role of CD4+CD25+highFoxp3+CD62L+ Regulatory T Cells and Invariant NKT Cells in Human Allogeneic Hematopoietic Stem Cell Transplantation

  2010cited by this paper
• Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402

  2010cited by this paper
• HLA-haploidentical stem cell transplantation for hematologic malignancies.

  2010cited by this paper
• Unmanipulated HLA-mismatched/haploidentical blood and marrow hematopoietic stem cell transplantation.

  2010cited by this paper
• CsA exposure is associated with acute GVHD and relapse in children after SCT

  2010cited by this paper
• Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias.

  2010cited by this paper
• Natural killer alloeffector responses in haploidentical hemopoietic stem cell transplantation to treat high-risk leukemias.

  2010cited by this paper
• Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif

  2010cited by this paper
• Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.

  2010cited by this paper
• Vγ9Vδ2 T Lymphocytes Efficiently Recognize and Kill Zoledronate-Sensitized, Imatinib-Sensitive, and Imatinib-Resistant Chronic Myelogenous Leukemia Cells

  2010cited by this paper
• Role of the plasma membrane leaflets in drug uptake and multidrug resistance

  2010cited by this paper
• Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia.

  2010cited by this paper
• The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis

  2010cited by this paper
• NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.

  2010cited by this paper
• Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.

  2010cited by this paper
• HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism.

  2009cited by this paper
• High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia

  2009cited by this paper
• Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity.

  2009cited by this paper
• Activating and inhibitory killer immunoglobulin‐like receptors (KIR) in haploidentical haemopoietic stem cell transplantation to cure high‐risk leukaemias

  2009cited by this paper
• Haploidentical hematopoietic stem-cell transplantation for non-Hodgkin lymphoma with bone marrow involvement

  2009cited by this paper
• Loss of mismatched HLA in leukemia after stem-cell transplantation.

  2009cited by this paper
• Interleukin-17–Producing T-Helper Cells as New Potential Player Mediating Graft-Versus-Host Disease in Patients Undergoing Allogeneic Stem-Cell Transplantation

  2009cited by this paper
• Haematopoietic stem cell transplantation for thalassaemia in Chinese patients.

  2009cited by this paper
• Outcome of 93 patients with relapse or progression following allogeneic hematopoietic cell transplantation

  2009cited by this paper
• Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.

  2009cited by this paper
• HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILD HEMATOLOGIC MALIGNANCIES WITH G-CSF-MOBILIZED MARROW GRAFTS WITHOUT T-CELL DEPLETION: A Single-Center Report of 45 Cases

  2009cited by this paper
• Increase in FOXP3+ regulatory T cells in GVHD skin biopsies is associated with lower disease severity and treatment response.

  2009cited by this paper
• Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.

  2009cited by this paper
• The impact of graft composition on clinical outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic SCT

  2009cited by this paper
• Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.

  2009cited by this paper
• Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers.

  2009influential reference
• HLA-haploidentical blood and bone marrow transplantation with anti-thymocyte globulin: long-term comparison with HLA-identical sibling transplantation.

  2009cited by this paper
• Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference.

  2009cited by this paper
• Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.

  2009cited by this paper
• A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD.

  2009cited by this paper
• Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance.

  2009cited by this paper
• CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.

  2009cited by this paper
• Stem cell transplant in the treatment of childhood biphenotypic acute leukemia

  2009cited by this paper
• Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation.

  2009cited by this paper
• Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematologic malignancies in children.

  2009cited by this paper
• The history and future prospective of haplo-identical stem cell transplantation.

  2008cited by this paper
• Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children.

  2008cited by this paper
• HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: Improved outcomes in patients in accelerated phase and blast crisis phase

  2008cited by this paper
• Mechanism of relapse in pediatric acute lymphoblastic leukemia

  2008cited by this paper
• A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation.

  2008cited by this paper
• Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis.

  2008cited by this paper
• NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation.

  2008cited by this paper
• Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application

  2008cited by this paper
• Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor.

  2008influential reference
• HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

  2008cited by this paper
• Donor lymphocyte infusions: the long and winding road: how should it be traveled?

  2008cited by this paper
• Immune Reconstitution after Haploidentical Hematopoietic Cell Transplantation: Impact of Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts

  2008cited by this paper
• Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation

  2007cited by this paper
• Outcome of Non-T-Cell-Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation from Family Donors in Children and Adolescents

  2007cited by this paper
• Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.

  2007cited by this paper
• The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation.

  2007cited by this paper
• Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment.

  2007cited by this paper
• Natural killer cell alloreactivity in allogeneic hematopoietic transplantation

  2007cited by this paper
• CD3+ cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin.

  2007cited by this paper
• Haploidentical stem cell transplantation for children with acute leukaemia

  2006cited by this paper
• HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants.

  2006cited by this paper
• Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.

  2006cited by this paper
• Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies

  2006cited by this paper
• Natural killer cell recognition of missing self and haploidentical hematopoietic transplantation.

  2006cited by this paper
• Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation.

  2006cited by this paper
• Human leukocyte antigen haploidentical hematopoietic stem cell transplantation: indications and tentative outcomes in Japan.

  2005cited by this paper
• Comparison of Killer Ig-Like Receptor Genotyping and Phenotyping for Selection of Allogeneic Blood Stem Cell Donors1

  2005cited by this paper
• Pregnancy induces minor histocompatibility antigen-specific cytotoxic T cells: implications for stem cell transplantation and immunotherapy.

  2004cited by this paper
• Transplantation of haploidentically mismatched stem cells for the treatment of malignant diseases

  2004cited by this paper
• Differential immunogenicity of paternal HLA Class I antigens in pregnant women.

  2003cited by this paper
• Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions.

  2003cited by this paper
• Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation.

  2002cited by this paper
• Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants

  2002cited by this paper
• Pregnancy can induce long-persisting primed CTLs specific for inherited paternal HLA antigens.

  2001cited by this paper
• MHC antigens and tumor escape from immune surveillance.

  2001cited by this paper
• Antigen-processing machinery breakdown and tumor growth.

  2000cited by this paper
• Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia.

  2000cited by this paper
• Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation

  1999cited by this paper
• Donor lymphocyte infusions

  1996cited by this paper
• Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.

  1996cited by this paper
• Immunoreconstitution in severe combined immunodeficiency after transplantation of HLA-haploidentical, T-cell-depleted bone marrow.

  1984cited by this paper
• SELF-MUTILATION IN LESCH-NYHAN SYNDROME

  1974cited by this paper
• Leucocyte Antibodies in Sera of Pregnant Women

  1959cited by this paper

• Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study

  2020cites this paper
• Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia

  2016cites this paper
• Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study

  2014cites this paper
• The TNF receptor-ligands 4-1BB-4-1BBL and GITR-GITRL in NK cell responses

  2013cites this paper
• Donor Bone Marrow-Derived Stem Cells Contribute to Oral Squamous Cell Carcinoma Transformation in a Recipient After Hematopoietic Stem Cell Transplantation

  2012cites this paper
• Different mechanisms causing loss of mismatched human leukocyte antigens in relapsing t(6;11)(q27;q23) acute myeloid leukemia after haploidentical transplantation

  2012cites this paper
• Incidence of extramedullary relapse after haploidentical SCT for advanced AML/myelodysplastic syndrome

  2012cites this paper